| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
JIN MEDICAL INTERNATIONAL LTD.$2.19
+0.19 (+9.53%)
D 35Pipeline Score MedTech · Clinical
Market Cap
18.59 M
EPS
0.15
P/E Ratio
15.61 $
Value Trade
566.88 K
1.09 %
Week
11 %
1 Month
-16.36 %
3 Month
-53.22 %
6 Month
-70.31 %
5 Year
-70.31 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
76.03 K
52 Week Range
1.64 - 17.18
% held by Insiders
76.61 %
% held by Institutions
0.06 %
Enterprise Value
7.40 M
Total Shares
156.29 M
Short %
0.43 %
Float Shares
37.82 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for JIN MEDICAL INTERNATIONAL LTD.
21Total events
0Upcoming
4Tier-1 (high impact)
2023 – 2026Coverage
Event history 2
TBD
▲Manufacturing MilestoneCMC / Inspection
Subscribe to view catalyst details
TBD
▼Reverse Stock SplitCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D35
Pipeline Score $19M
Pipeline ValueValuation Signal
5
Drugs Scored1.0x
rNPV / MCap Top 49%
Micro Cap (rank 467 of 913)
Percentile RankJIN MEDICAL INTERNATIONAL LTD. faces pipeline headwinds (35/100), with $1.3B risk-adjusted pipeline value, led by AK104 in Locally Advanced Rectal Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AK104 Small molecule | Locally Advanced Rectal Cancer | Phase 2 | NCT05794750 | 19% | $491M | NOT YET_RECRUITING | 50 | - | - | Apr 24, 2027 | - | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZJYL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ZJYL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZJYLJin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
Jin Medical International Ltd. has announced its compliance with Nasdaq's minimum bid price requirement after its shares maintained a closing price of at least $1.00 for more than ten consecutive business days. The company, which specializes in rehabilitation medical equipment, plans to continue focusing on its core operations and strategic initiatives. This development reflects positively on Jin Medical's market position.
Read more →ZJYLJin Medical International Ltd. Announces 1-for-20 Share Combination as Part of Strategic Nasdaq Compliance Initiative
Jin Medical International Ltd. announced a 1-for-20 share combination as part of a strategic initiative to maintain Nasdaq compliance and strengthen its long-term capital structure. Effective March 16, 2026, this stock combination follows the approval from a recent extraordinary general meeting. The reclassification of shares will reduce both Class A and Class B shares significantly, aimed at enhancing governance and financial health. The company continues to operate with established plans for extensive manufacturing capabilities in China.
Read more →ZJYLJin Medical International Ltd. Announces 1-for-20 Share Combination as Part of Strategic Nasdaq Compliance Initiative Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a...
Jin Medical International Ltd. announced a 1-for-20 share combination to comply with Nasdaq listing requirements. This strategic move, approved by the Board of Directors, will reduce the number of outstanding shares significantly. The reclassification into Class A and Class B shares aims to strengthen the company's capital structure and governance. The changes will take effect on March 16, 2026.
Read more →ZJYLJin Medical CEO Fireside Chat
Jin Medical International Ltd. hosted a CEO Fireside Chat on February 2, 2026, where CEO Dr. Erqi Wang discussed the company's strategic priorities and long-term growth plans. Key points included the implementation of reverse stock splits to regain Nasdaq compliance and improve market perception. The company plans to focus on disciplined capital allocation, enhancing manufacturing efficiency, and the strategic importance of their new Chuzhou facility expected to launch full production by April 2026. Overall, management aims to navigate industry challenges while prioritizing sustainable growth in the coming years.
Read more →ZJYLJin Medical CEO Fireside Chat Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider ...
Jin Medical International Ltd. hosted a CEO Fireside Chat where CEO Dr. Erqi Wang discussed the company's strategic priorities, including a potential reverse stock split for compliance. He outlined long-term objectives focused on manufacturing efficiency, product commercialization, and expansion into new markets. The new Chuzhou factory is a key investment aimed at enhancing production capabilities and competitiveness.
Read more →ZJYLJin Medical International Ltd. To Host Management Fireside Chat
Jin Medical International Ltd. announced that its CEO and management team will host a fireside chat on February 1, 2026, focusing on strategic priorities and growth opportunities. The company also revealed the launch of its redesigned corporate website, improving accessibility for stakeholders. Jin Medical, a prominent player in the rehabilitation medical equipment sector, is actively expanding its operations with a new larger manufacturing facility in Anhui Province.
Read more →ZJYLJin Medical International Ltd. To Host Management Fireside Chat Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading...
Jin Medical International Ltd. will host a fireside chat on February 1, 2026, led by its CEO and management team. The discussion aims to provide insights into the company's strategic priorities and growth plans. Additionally, Jin Medical has launched an updated corporate website where the chat will be webcast. The company is expanding its manufacturing capabilities in China.
Read more →ZJYLJin Medical Announces the Official Commencement Date of Chuzhou Facility Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading...
Jin Medical International Ltd. has announced the commencement date for its new manufacturing facility in Chuzhou, Anhui Province, China. The facility is expected to begin full production by the end of April 2026, focusing on mid-to-high-end electric wheelchairs and mobility scooters. This expansion aims to enhance the company's manufacturing capabilities and respond to growing global demand for assistive devices.
Read more →ZJYLJin Medical Announces the Official Commencement Date of Chuzhou Facility Changzhou, China
Jin Medical International Ltd. has announced the commencement of its new manufacturing facility in Chuzhou, Anhui Province, China, expected to begin full production by April 2026. The facility will focus on manufacturing mid-to-high-end electric wheelchairs and mobility scooters, enhancing Jin Medical's capacity to meet growing global demand. Completion of this project is aligned with the company's strategic goals of optimizing production capacity and improving supply chain resilience. The location offers significant geographic advantages within the manufacturing hub of the Yangtze River Delta.
Read more →ZJYLJin Medical International Ltd. Management Plans For Fireside Chat Changzhou, China
Jin Medical International Ltd. has announced that its management team will host a fireside chat on February 1, 2026, to discuss the company's strategic priorities and capital structure. The discussion will address recent market developments while providing transparency into management's decision-making process. Jin Medical emphasizes its strong liquidity position and is exploring various strategic options to strengthen its competitive stance in the rehabilitation medical equipment market.
Read more →ZJYLJIN MEDICAL INTERNATIONAL LTD. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People's Republic of China NOTICE OF 2026 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held at 10:00 p.m
Jin Medical International Ltd. announced an extraordinary general meeting of shareholders scheduled for January 30, 2026, to discuss several key proposals. These include increasing the authorized share capital, the creation of dual-class shares, and potential consolidations of shares. Shareholders will also consider the adoption of a new equity incentive plan. Importantly, the Board unanimously recommends approval of all proposals to enhance the company's capital structure and governance.
Read more →ZJYL▼ -5.6%on this news· ran to +41% by day 3
JIN MEDICAL INTERNATIONAL LTD. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS March 31
Jin Medical International Ltd. has reported its unaudited condensed consolidated balance sheets as of March 31, 2025. The company showed an increase in current assets, notably a rise in cash reserves, but faced ongoing struggles with declining revenues and a net loss for the period. The company's total liabilities also increased, leading to a significant comprehensive loss attributed to challenges in foreign currency translation. Despite maintaining a positive cash flow from operating activities, the financial outlook indicates underlying issues that could impact future performance.
Read more →ZJYLJin Medical Launches Production at Plant No. 3, Accelerating Global Delivery from the Chuzhou Manufacturing Facility Beijing, China
Jin Medical International Ltd. has officially launched production at Plant No. 3 in Chuzhou, Anhui, China. This new facility is part of the company's strategy to accelerate global delivery of rehabilitation medical equipment, with a production capacity of 200,000 units per year. Emphasizing intelligent manufacturing techniques, Jin Medical aims to enhance its supply chain and contribute to meeting diverse global health needs. The company's product range includes wheelchairs and wellness devices, targeting international markets including Istanbul, Jerusalem, and Tokyo.
Read more →ZJYLJin Medical International Ltd. - Nasdaq Minimum Bid Price Non-Compliance Changzhou City, China
Jin Medical International Ltd. announced it received a deficiency notice from Nasdaq for failing to maintain the minimum bid price of $1.00 for its shares. The compliance period granted by Nasdaq is 180 days, and the Company aims to regain compliance during this time. If the bid price fails to reach the minimum within this period, additional time may be available, but the Company still faces potential delisting risks. Operations continue, with the Company examining options to address the situation.
Read more →ZJYLJin Medical Accelerates Chuzhou Facility Construction to Unlock Annual Production Capacity of RMB 300 Million Chuzhou City, China
Jin Medical International Ltd. is making significant advancements in the construction of its Chuzhou manufacturing facility, which is projected to achieve an annual production capacity of RMB 300 million. The facility aims to produce mid-to-high-end electric wheelchairs and mobility scooters, with trial production set for May 2025 and full completion by October 2025. This expansion is aligned with the growing demand for assistive devices due to global aging, bolstering Jin Medical's manufacturing capabilities and market position.
Read more →ZJYLConstruction of JinMed's New Facility Begins in Chuzhou, China Chuzhou City, China
Jin Medical International Ltd. has announced the initiation of construction for a new manufacturing facility in Chuzhou City, Anhui Province, China. This facility aims to serve as a high-end production site for wheelchairs, electric wheelchairs, and other healthcare products. The new site is expected to enhance JinMed's production capacity and innovative offerings in the assistive technologies industry. The facility is targeted to begin operations in 2025, marking a significant step forward for the company's growth and technological advancement.
Read more →ZJYLJIN MEDICAL INTERNATIONAL LTD. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS March 31
Jin Medical International Ltd. released its unaudited condensed consolidated financial statements for March 31, 2024. The company reported total assets of approximately $41.16 million, marking an increase from $32.90 million in the previous year. Notably, net income attributable to Jin Medical increased to around $1.79 million. The firm continues to show resilience in its operations, despite minor fluctuations in revenue and expenses.
Read more →ZJYL▼ -13%on this news
JIN MEDICAL INTERNATIONAL LTD. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People's Republic of China NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held at 9.30 a.m. Beij
Jin Medical International Ltd. is holding an extraordinary general meeting of shareholders on January 30, 2024. The meeting will address a proposal to subdivide issued and unissued shares, transforming each share into twenty new shares with a reduced par value. Shareholders of record as of January 12, 2024, are eligible to vote, and proxy materials have been sent out to ensure participation. The Board has unanimously recommended approval of the proposals.
Read more →ZJYL▲ +11.9%on this news· ran to +275% by day 3
JIN MEDICAL INTERNATIONAL LTD. Enters into Memorandum of Understanding to Acquire Medical Equipment Sharing Platform Changzhou City, China
JIN MEDICAL INTERNATIONAL LTD. has signed a Memorandum of Understanding to explore the acquisition of Jiangsu Zhongjin Kanglu, a company specializing in medical equipment sharing. This acquisition aims to enhance healthcare service access through better equipment availability. A due diligence process is set to evaluate the acquisition's feasibility by the end of December 2023, with detailed negotiations expected to begin in March 2024. However, there is no guarantee that the acquisition will proceed as planned.
Read more →ZJYLJIN MEDICAL INTERNATIONAL LTD. Empowers "Lao Le Hui" Assisted Bathing Project with Portable Nano-thermal Therapy Bath Changzhou City, China
Jin Medical International Ltd. has announced its collaboration with the 'Lao Le Hui' Assisted Bathing Project to provide 1,000 portable nano-thermal therapy baths. This initiative, aimed at improving care for disabled and semi-disabled elderly individuals in Shanghai, targets assistance for 100,000 people and training 2,000 attendants over the next two years. The project emphasizes community involvement and aims to enhance the quality of elderly care through advanced bathing technology, which promises a more comfortable bathing experience. Chairman Wang Erqi expressed commitment to supporting the project's goals and expanding its reach.
Read more →ZJYL▲ +9.8%on this news· ran to +24% by day 3shared move
JIN MEDICAL INTERNATIONAL LTD. Secures RMB66 Million in Orders for Innovative Micro-Hyperbaric Oxygen Chamber Equipment Changzhou City, China
Jin Medical International Ltd. announced the acquisition of RMB 66 million in orders for their innovative Micro-Hyperbaric Oxygen Chamber equipment from Conlo Industrial Development. This order includes 200 units each of the S-type and M-type chambers, which are designed for therapeutic use. The strategic partnership aims to meet the increasing demand in the healthcare sector over the next three years, with plans to supply a total of 20,000 oxygen chambers for both human and pet use. The chambers are anticipated to enhance health and well-being through various therapeutic applications.
Read more →ZJYL▼ -18.3%on this news
INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JIN MEDICAL INTERNATIONAL LTD. AND SUBSIDIARIES TABLE OF CONTENTS Consolidated Financial Statements Unaudited Condensed Consolidated Balance Sheets as of
Jin Medical International Ltd. released its unaudited condensed consolidated financial statements for the six months ending March 31, 2023. The company reported a net income of $1.77 million, reflecting an increase from the previous year. Significant growth in total assets and revenue was noted, with total assets rising to $31.02 million. However, there were also challenges, including substantial cash outflows in investing activities and persistently high operating expenses.
Read more →ZJYLJin Medical International Ltd. Announces Exercise of the Underwriters' Over-Allotment Option Changzhou City, China
Jin Medical International Ltd., based in Changzhou City, China, has announced the partial exercise of the underwriters' over-allotment option related to its IPO. This transaction allowed the company to raise an additional $378,840 at the IPO price of $8.00 per share, adding to the previously announced gross proceeds of $8,000,000. The growth in capital supports Jin Medical's operations in manufacturing and developing wheelchairs and living aids, a sector vital for people with disabilities and the elderly.
Read more →ZJYLJin Medical International Ltd. Announces Pricing of $8,000,000 Initial Public Offering Changzhou City, China
Jin Medical International Ltd. has successfully priced its initial public offering at $8.00 per share, raising $8,000,000 in total gross proceeds. The 1,000,000 ordinary shares will be listed on the Nasdaq Capital Market starting March 28, 2023, with the offering expected to close on March 30, 2023. The funds from the offering will be allocated to various activities such as R&D, marketing, and expansion of production capabilities. Web links to the final prospectus and SEC filings are also provided in the announcement.
Read more →Competitive Position
How ZJYL ranks across every disease it competes inCompetitive Position is a premium feature
See how ZJYL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial